Modest Blood Pressure Reductions With DASH-Like Diet in Type 2 Diabetes
The reduced-sodium component of the experimental diet likely drove the reduction in BP
Related Articles
Upadacitinib in Atopic Dermatitis: Long-Term Effectiveness, Safety in Adolescents
Upadacitinib was found to be effective over the long-term in adolescents with moderate-to-severe atopic dermatitis (AD). Investigators analyzed data from three phase 3 randomized clinical…
Dual Approach the Best Remedy for Aortic Stenosis, Amyloidosis: Registry
The advent of ATTR-specific drugs, though pricey, is enabling better survival in these overlapping diseases, researchers say.
Polypill Approved for Hypertension, Including as Initial Therapy
The pill comes in three doses and contains telmisartan, amlodipine, and indapamide
GLP-1 Drug Can Cause Rare, Potentially Blinding Side Effect, EMA Warns
Non-arteritic anterior ischemic optic neuropathy could affect one in 10,000 semaglutide users
Ludmil Alexandrov, PhD, on Use of AI to Predict HRD and Response Directly From Routine Biopsy Slides
A novel artificial intelligence (AI) protocol called DeepHRD was able to predict homologous recombination deficiency (HRD) in ovarian and breast cancers directly from routine histopathological…
Recent Developments in Bladder Cancer
Biomarker-guided bladder preservation, perioperative durvalumab, personalized radiotherapy
Private Equity in Heart Failure Care; Oral PCSK9 Inhibitor Wins; First Robotic TAVR
Recent developments of interest in cardiovascular medicine
Maker of Sexual Desire Drug Addyi Gets FDA Warning Letter
Not the first time Sprout Pharmaceuticals has been warned for ‘misleading’ promotion
Should AMA ‘Support’ a Registry to Track Side Effects of GLP-1 Drugs?
Some delegates praised the idea, while others argued it would be redundant
FDA Officials Lay Out Vision for Agency
Makary and Prasad again turn to a medical journal their boss has called ‘corrupt’